Skip to main content

Table 4 Diagnostic performance of the prediction model in diagnosing CSPCa in PSA gray zone patients

From: 68Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone

 

Sensitivity (95% CI)

Specificity (95% CI)

AUC (95% CI)

Model

86.21% (69.44-94.50%)

86.54% (74.73-93.32%)

0.927 (0.8738-0.980)

68Ga-PSMA PET/CT

93.10% (76.97-99.15%)

76.92% (63.16-87.47%)

0.850 (0.762–0.938)

mpMRI

86.21% (68.34-96.11%)

44.23% (31.59-57.67%)

0.652 (0.532–0.773)

PSA

48.28% (31.39-65.57%)

75.00% (61.79-84.77%)

0.585 (0.447–0.724)

  1. CSPCa, clinically significant prostate cancer; PSA, prostate-specific antigen; 68Ga-PSMA PET/CT, 68Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography; mpMRI, multiparametric magnetic resonance imaging
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us